Other Income/Expenses (Net)

$137.03M

TTM · Period ending: Jun 30, 2026 · USD

Latest reported$137.03Mperiod endingJun 30, 2026

LGND Other Income/Expenses (Net) (-$5.50M → $137.03M)

Annual Other Income/Expenses (Net)

High-resolution chart · PNG

LGND other income/expenses (net) history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Ligand Pharmaceuticals Inc Other Income/Expenses (Net) — Annual fiscal periods (USD)
Period ending	Other Income/Expenses (Net) (USD)
Dec 31, 2025	111,761,000
Dec 31, 2024	25,124,000
Dec 31, 2023	51,718,000
Dec 31, 2022	32,974,000
Dec 31, 2021	-31,646,000
Dec 31, 2020	-36,208,000
Dec 31, 2019	-10,437,000
Dec 31, 2018	9,603,000
Dec 31, 2017	-10,845,000
Dec 31, 2016	-35,925,000
Dec 31, 2015	8,000,000
Dec 31, 2014	-8,324,000
Dec 31, 2013	-5,737,000
Dec 31, 2012	-4,439,000
Dec 31, 2011	-2,860,000
Dec 31, 2010	13,901,000
Dec 31, 2009	95,000
Dec 31, 2008	-239,000
Dec 31, 2007	6,719,000
Dec 31, 2006	-96,193,000
Dec 31, 2005	-9,869,000
Dec 31, 2004	-7,537,000
Dec 31, 2003	-20,393,000
Dec 31, 2002	-8,359,000
Dec 31, 2001	-8,363,000
Dec 31, 2000	-825,000
Dec 31, 1999	-707,000
Dec 31, 1998	-43,000,000
Dec 31, 1997	-61,300,000
Dec 31, 1996	3,700,000
Dec 31, 1995	-33,800,000
Dec 31, 1994	-5,500,000